Brief: Eledon Pharmaceuticals Announces First Participant Dosed In Phase 2 BESTOW Trial
05/09/2023 12:02
Sept 5 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED
IN
PHASE 2 BESTOW TRIAL EVALUATING TEGOPRUBART FOR THE PREVENTION
OF REJECTION IN KIDNEY TRANSPLANTATION
Source text for Eikon: ID:nGNX6CkRkQ
Further company coverage: ELDN.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial